Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

A case of ROS1-rearranged lung adenocarcinoma exhibiting pleural effusion caused by crizotinib.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: Wiley Publishing Asia Pty Ltd Country of Publication: Singapore NLM ID: 101531441 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1759-7714 (Electronic) Linking ISSN: 17597706 NLM ISO Abbreviation: Thorac Cancer Subsets: MEDLINE
    • بيانات النشر:
      Publication: November 2012- : Singapore : Tianjin : Wiley Publishing Asia Pty Ltd ; Tianjin Lung Cancer Institute
      Original Publication: Richmond, Vic. : Tianjin : Blackwell Pub. Asia Pty Ltd. ; Tianjin Lung Cancer Institute
    • الموضوع:
      Gene Rearrangement*; Adenocarcinoma of Lung/*drug therapy ; Antineoplastic Agents/*adverse effects ; Crizotinib/*adverse effects ; Lung Neoplasms/*drug therapy ; Pleural Effusion/*pathology ; Protein-Tyrosine Kinases/*genetics ; Proto-Oncogene Proteins/*genetics; Adenocarcinoma of Lung/genetics ; Adenocarcinoma of Lung/pathology ; Adult ; Female ; Humans ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Pleural Effusion/chemically induced ; Prognosis
    • نبذة مختصرة :
      Reports of crizotinib-induced pleural effusion in non-small cell lung cancer (NSCLC) are limited. A 35-year-old Japanese woman was diagnosed with ROS1-rearranged lung adenocarcinoma (primary left lower lobe, cT4N3M1c). Crizotinib was administered as first-line therapy, and the primary and mediastinal hilar lymph node metastases rapidly shrank. On the fourth day of treatment, chest X-ray demonstrated contralateral pleural effusion. On the 41st day of treatment, crizotinib was discontinued because of grade 3 neutropenia. Examination including surgical thoracoscopy did not reveal causative findings, and the continued cessation of drug administration enabled the right pleural effusion to decrease gradually and disappear, suggesting that this event was a side effect of crizotinib. The disease did not progress even though the drug was withdrawn for more than one year. In conclusion, crizotinib was considered to cause pleural effusion as an adverse event in a case of ROS1-rearranged lung adenocarcinoma with a complete response.
      (© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.)
    • References:
      J Clin Oncol. 2012 Mar 10;30(8):863-70. (PMID: 22215748)
      J Thorac Oncol. 2015 Aug;10(8):1148-55. (PMID: 26200268)
      Jpn J Clin Oncol. 2014 Aug;44(8):762-4. (PMID: 24872405)
      Clin Cancer Res. 2012 Sep 1;18(17):4570-9. (PMID: 22919003)
      Nat Commun. 2019 Apr 2;10(1):1486. (PMID: 30940805)
      N Engl J Med. 2014 Nov 20;371(21):1963-71. (PMID: 25264305)
      Nature. 2014 Apr 10;508(7495):222-7. (PMID: 24695225)
      J Clin Oncol. 2013 Jan 1;31(1):e15-7. (PMID: 23169500)
      Acta Oncol. 2014 Jan;53(1):158-60. (PMID: 23750540)
      J Thorac Oncol. 2019 Apr;14(4):672-682. (PMID: 30521972)
      J Thorac Dis. 2019 Jul;11(7):2965-2972. (PMID: 31463126)
      Oncogene. 2000 Nov 20;19(49):5548-57. (PMID: 11114734)
    • Contributed Indexing:
      Keywords: Complete response; ROS1 rearrangement; crizotinib; lung adenocarcinoma; pleural effusion
    • الرقم المعرف:
      0 (Antineoplastic Agents)
      0 (Proto-Oncogene Proteins)
      53AH36668S (Crizotinib)
      EC 2.7.10.1 (Protein-Tyrosine Kinases)
      EC 2.7.10.1 (ROS1 protein, human)
    • الموضوع:
      Date Created: 20200521 Date Completed: 20210311 Latest Revision: 20240730
    • الموضوع:
      20250114
    • الرقم المعرف:
      PMC7327693
    • الرقم المعرف:
      10.1111/1759-7714.13496
    • الرقم المعرف:
      32433811